Search results
Results From The WOW.Com Content Network
GSK Plc (NYSE:GSK) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on patents it developed. Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday. Read Next:
Price Action: MRNA stock is up 5.40% at $38.84 at last check Monday. Read Next: Newmont Strikes Deal To Sell Musselwhite Gold Mine, Bolstering $2 Billion Asset Sales Streak
On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 trial of V940 (mRNA-4157). V940 is an investigational ...
Moderna held its annual R&D day this week. Moderna's (NASDAQ: MRNA) struggles may last a little longer than expected. The biotech company had seen both sales and its stock price plummet as demand ...
I am lucky that I get to write about investing in Moderna (NASDAQ:MRNA) stock on the day after the FDA panel approves its Covid-19 vaccine for emergency use. I expected to be writing about a ...
Monday, Moderna, Inc.’s (NASDAQ:MRNA) manufacturing facility in Laval, Quebec, received a Drug Establishment License (DEL) from Health Canada. This certification affirms the facility’s ...
Vaccine maker Moderna (MRNA) is on everyone’s radar, with shares rocketing from the $20 level in January to over $60 today. Moderna stock got another small boost yesterday after the inventor of ...
Moderna's stock dropped Monday despite positive news over the weekend from a Phase 2 trial of its personalized cancer vaccine in partnership with Merck ().The data from the trial provided support ...